Clinical trials: Pyoderma Gangrenosum
Pyoderma Gangrenosum
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers.
- Trial name
- NCT06624670
- Testing
- Spesolimab, Prednisone, Prednisolone
- Where
- 104 sites in United States, Argentina and 19 more
- Volunteers
- 90 people
- Sponsor
- LEO Pharma
Pyoderma Gangrenosum
A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum
This study aims to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 Injection in patients with pyoderma gangrenosum.
- Trial name
- NCT07444684
- Testing
- SHR-1139 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Pyoderma Gangrenosum
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum
- Trial name
- NCT05964413
- Testing
- vilobelimab
- Where
- 50 sites in United States, Australia and 8 more
- Volunteers
- 54 people
- Sponsor
- InflaRx GmbH
Pyoderma Gangrenosum
A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)
Pyoderma Gangrenosum (PG) is a rapidly progressive disease and presents as painful, single or multiple lesions, with several clinical variants, in different locations, with a nonspecific histology, which makes the diagnosis…
- Trial name
- NCT04750213
- Where
- 46 sites in Japan
- Volunteers
- 60 people
- Sponsor
- AbbVie
Pyoderma Gangrenosum
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.
- Trial name
- NCT01965613
- Testing
- Xilonix
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Janssen Research & Development, LLC
Pyoderma Gangrenosum
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
The purpose of this study is to determine whether vilobelimab (development name: IFX-1) is safe and effective in the treatment of pyoderma gangrenosum.
- Trial name
- NCT03971643
- Testing
- vilobelimab
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 19 people
- Sponsor
- InflaRx GmbH
Solid Tumors
A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors
The primary objective of this study is to evaluate the tolerability and safety profile of farletuzumab ecteribulin in participants with solid tumors.
- Trial name
- NCT03386942
- Testing
- Farletuzumab Ecteribulin
- Where
- 10 sites in Japan
- Volunteers
- 82 people
- Sponsor
- Eisai Inc.
Pyoderma Gangrenosum
Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum
The purpose of this Phase 2a, open label, proof-of-concept clinical study is to assess the efficacy and safety of etrasimod (APD334) in patients with Pyoderma Gangrenosum.
- Trial name
- NCT03072953
- Testing
- APD334
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 2 people
- Sponsor
- Arena Pharmaceuticals
Pyoderma Gangrenosum
A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan
This study is designed to investigate the efficacy, safety and pharmacokinetics of adalimumab in subjects in Japan with active ulcer(s) due to Pyoderma Gangrenosum (PG).
- Trial name
- NCT03311464
- Testing
- adalimumab
- Where
- 20 sites in Japan
- Volunteers
- 22 people
- Sponsor
- AbbVie
Pyoderma Gangrenosum
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).
- Trial name
- NCT02315417
- Testing
- gevokizumab, gevokizumab open-label
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- XOMA (US) LLC
Pyoderma Gangrenosum
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers
- Trial name
- NCT02318914
- Testing
- gevokizumab
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 15 people
- Sponsor
- XOMA (US) LLC
Pyoderma Gangrenosum
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).
- Trial name
- NCT02326740
- Testing
- gevokizumab, gevokizumab open-label
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 9 people
- Sponsor
- XOMA (US) LLC
Pyoderma Gangrenosum
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.
- Trial name
- NCT01882504
- Testing
- gevokizumab
- Where
- 19 sites in United States
- Volunteers
- 8 people
- Sponsor
- XOMA (US) LLC